Epilepsy Drug Lacosamide Shows Promise for Reversing Osteoarthritis Damage in Early Research

Early research suggests that lacosamide, a drug currently approved to treat epilepsy, may be able to reverse cartilage damage caused by osteoarthritis, a finding that could open a new treatment path for one of the world's most common joint diseases.

Scientists found that lacosamide reduced inflammation in joint tissue and promoted cartilage repair in laboratory models of osteoarthritis. The drug works by modulating sodium channels in nerve cells, and researchers believe a similar mechanism may play a role in the inflammatory processes that drive cartilage breakdown.

Osteoarthritis affects hundreds of millions of people worldwide and is a leading cause of disability, particularly in older adults. Current treatments focus on managing pain and slowing the disease's progression, but no approved drug has been shown to reverse cartilage damage once it has occurred.

The discovery that an existing, approved drug might have this effect is significant because it could accelerate the path to clinical trials. Lacosamide already has a well-established safety profile from its use in epilepsy patients, which reduces some of the early-stage uncertainty that comes with developing a new compound from scratch.

Researchers cautioned that results in laboratory models do not always translate to human patients, and that the drug's effects on joint tissue in living people remain unknown. They called for carefully designed human trials to test whether the findings hold up outside the laboratory.

If confirmed in clinical trials, lacosamide could represent the first disease-modifying treatment for osteoarthritis, a category of drug that has long been sought but never successfully developed for this condition.

The research was highlighted in recent scientific news coverage as one of several promising early-stage discoveries in joint disease research.